CytomX Therapeutics (Nasdaq: CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today entered into a collaboration with The University of ...

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...

Natural killer (NK) cells became markedly better at killing cancer cells after scientists removed key gene targets identified through a new genome-wide CRISPR screening tool, according to new research ...

Natural killer cells, also referred to as NK cells, play several major roles in the body's defense against cancers like renal cell carcinoma. Natural killer cells, also referred to as NK cells, play ...

ImmunityBio Inc. IBRX shares are up on Friday morning as the company completed its manufacturing engineering programs for its NK cell therapy platform. • ImmunityBio shares are powering higher. Why is ...

Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with the potential to overcome key limitations of current chimeric antigen ...

Immune evasion continues to limit the effectiveness of cancer immunotherapies. Among emerging regulatory molecules, transfer RNA-derived small RNAs (tsRNAs of 13-48 nucleotides), generated through ...

Cancer is one of the most serious health problems in the world. Every year, millions of people are diagnosed with different ...